Zoom
As the landscape of HIV treatment and prevention evolves, long-acting formulations are emerging as a transformative tool in improving treatment adherence — expanding choice and ensuring equitable access, particularly for communities most in need.
The long-acting injectable, lenacapavir LA, has shown immense promise for HIV prevention, with results from clinical trials showing that 99.9% of study participants who received lenacapavir LA did not acquire HIV.
Long-acting antiretroviral therapy (ART) could offer a critical opportunity to lessen the burden on people receiving ART and reduce the strain on health system resources, transforming HIV treatment and prevention globally. Despite this potential, the scale-up of these newer formulations faces the acute funding crisis caused by shifts in U.S. global health policy.
Date: April 17, 2025
Time: 3 – 4:30 p.m. SAST and CET / 9 – 10:30 a.m. ET
This webinar, jointly hosted with the NGO Delegation and Communities Delegation to the Unitaid Board, will explore the opportunities and challenges in making long-acting medicines for ART available to all who need them.
The discussion will bring together leading experts, advocates, and policymakers to:
- Provide an overview of the long-acting antiretroviral pipeline, including currently approved and future options
- Discuss the role of Unitaid in advancing access to long-acting interventions
- Explore implementation challenges and lessons from South Africa and Uganda
- Highlight community perspectives in the rollout of long-acting antiretrovirals, including national action and accountability and strategies for community engagement
Speakers:
- Carmen Pérez Casas, Senior Strategy Lead and PPPR Head, Unitaid
- Sharonann Lynch, Co-director, Center for Global Health Policy & Politics, O’Neill Institute
- Abdul-Fatawu Salifu, Alternate Board Member, Unitaid Communities Delegation
- Tracy Swan, Activist/Consultant, Global Health
- WD Francois Venter, Executive Director, Wits Ezintsha at the University of the Witwatersrand